Melanoma/Skin Cancer

Questions discussed in this category

Do you favor one treatment over the other? Do you find one treatment more effective than the other?

What is the current role for genetic profile testing (e.g. DecisionDx-SCC) in the treatment paradigm for cutaneous malignancies?

Have you utilized these gene-expression profiles in your practice? Is there sufficient data for this test to be used for clinical decisions?

1 Answer available

Would you change systemic therapy for metastatic melanoma on BRAF/MEK targeted therapy with excellent extracranial response, but with CNS-only progression?

1 Answer available

In what situation would you recommend relatlimab + nivolumab over ipilimumab + nivolumab in the treatment of metastatic melanoma?

3 Answers available

What dose-fractionation would you recommend for a small basal cell carcinoma of the nasal ala in a patient with poor performance status or transportation difficulties?

5 Answers available

What goes into your decision making when deciding between superficial radiation and Mohs surgery for cutaneous squamous cell carcinoma of the head and neck?

Size: 3 cm, cN0

2 Answers available

How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?

2 Answers available

How would you approach the post-operative radiation treatment volumes for a Merkel cell carcinoma of the hand?

Would you treat the primary site alone, include the hand and arm lymphatics to the epitrochlear nodes (one continious treatment volume from hand to el...

1 Answer available

How do you approach a patient with recurrent chest wall BRAF(+) mutated melanoma who developed multiple metastatic axillary nodes while on immunotherapy, now post axillary dissection for adjuvant radiation?

3 Answers available

What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?

Is T4 disease a contraindication?

1 Answer available

What is your approach to treating inoperable mucosal melanoma of the head and neck region?

What is the preferred dose, fractionation, and role of concurrent chemo?

1 Answer available

How often are you recommending adjuvant pembrolizumab for resected stage IIB/C melanoma patients?

Based on the KEYNOTE-716 study and Dec 2021 FDA approval

2 Answers available

What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?

2 Answers available

Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?

1 Answer available

How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?

Is completing nodal dissection warranted for surgical management?

1 Answer available

What radiation dose-fractionation regimen would you choose for squamous cell carcinoma of the great toe in a patient who declines surgery?

How would you counsel the patient on wound healing and potential complications in this region?

1 Answer available

How do you manage SCC metastasis to the parotid with unknown primary?

How would your management change in an elderly patient with no surgery verus superficial parotidectomy or total parotidectomy?

1 Answer available

Would you consider adjuvant radiation for a patient with recurrent pelvic node melanoma s/p immunotherapy and pelvic lymph node dissection with complete pathological response (only necrotic tissue; no viable melanoma)?

1 Answer available

What ENI/lymph node stations would you treat for a locally advanced SCC of the thumb?

1 Answer available

How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?

The SWOG 1801 trial showed improved event-free survival (EFS) in patients receiving neoadjuvant pembrolizumab followed by 15 cycles of adjuvant pembro...

1 Answer available

What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?

Do you prefer single agent PD-1 inhibitor or combination immunotherapy?

1 Answer available

How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?

Very-low-risk stage IIIA disease includes non-ulcerated lesions, primary ≤2 mm thickness, SLN metastasis <1 mm. Per NCCN the toxicity of adjuvan...

1 Answer available

In patients with skin squamous cell carcinoma invading the skull, what dose do you limit the brain when treating definitively with radiation?

2 Answers available

How would you approach a recurrent, cutaneous SCC of the face with high-risk features s/p resection?

Definitive radiation therapy > 5 years ago. Positive margins, PNI of 0.1 mm. What volume would you cover? Dose/fractionation?

1 Answer available

How do you approach an elderly patient (~80 years) with stage IIC melanoma post resection with oligometastatic brain lesion post intracranial resection which developed 2 years after treatment?

The patient's current PET scan showed no systemic disease. Due to his age, there is a concern of whether the patient would tolerate dual immunotherapy...

2 Answers available

How would you treat an elderly patient (ECOG 0-1) with locally advanced rectal cancer and synchronous Merkel cell cancer of the extremity requiring adjuvant RT?

Would you treat both at the same time? Does one need to be prioritized over the other? Does Xeloda have any efficacy against Merkel cell cancer? How...

4 Answers available

How would you manage a Merkel cell carcinoma that spontaneously regressed clinically in a patient medically high-risk for surgical resection/anesthesia?

How would you treat the primary tumor (located in the chest)? Would you treat the regional lymph nodes?

2 Answers available

How would you treat a periungual squamous cell carcinoma of the thumb?

2 Answers available

What surveillance plan would you recommend for stage IV melanoma patients who achieve a CR or stable PR response with immunotherapy?

1 Answer available

What is your preferred skin surface maximum dose constraint for skin brachytherapy?

1 Answer available

How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?

Is there a potential role for concurrent radiation therapy? What if the tumor is BRAF mutated?

2 Answers available

What surveillance imaging do you obtain for stage III melanoma patients after completing systemic adjuvant therapy?

1 Answer available

How do you approach patients with metastatic uveal melanoma not a candidate for tebentafusp-tebn?

2 Answers available

How would you manage a localized melanoma of the anal canal with sphincter involvement, but without nodal or distant disease?

1 Answer available

What electron beam dose/fractionation would you use for a recurrence basal cell carcinoma of the scalp adjacent to a split thickness skin graft?

1 Answer available

For merkel cell carcinoma of the eyelid, how do you approach post-operative management and what are the recommended radiation treatment volumes?

1 Answer available

Do you recommend an additional procedure for melanomas if there is tumor within 1-2mm of the margin?

2 Answers available

How do you approach patients with malignant melanoma who are disease free on immunotherapy for over 3 years?

1 Answer available

How do you approach patients with stage III melanoma for adjuvant treatment?

Which group of patients will benefit with observation versus adjuvant immunotherapy?

1 Answer available

What histologic findings most commonly lead you to order additional staining for potential desmoplastic melanoma?

Especially in cases where the MIS portion is obvious but the dermal component may not be.

1 Answer available

How do you approach patients with polypoid/nodular melanoma for adjuvant therapy when Breslow depth is not available on pathology?

In this scenario do we use the actual tumor size for "T staging".

2 Answers available

How do you approach the management of basal cell carcinoma with single lymph node involvement?

In patients with no apparent skin involvement but lymph-node showing basal cell carcinoma with extracapsular extension. Would this warrant radiation o...

3 Answers available

Do your radiation treatment margins change for cutaneous basal cell carcinoma in the adjuvant setting compared to cutaneous squamous cell carcinoma?

What margins do you use for each cancer for photons vs electrons? If your margins differ between cBCC and cSCC, why?

2 Answers available

Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

4 Answers available

Would you continue cemiplimab or pembrolizumab adjuvantly, following resection of initially unresectable cutaneous squamous cell carcinoma?

Do you base your decision on extent of residual disease? Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...

4 Answers available

Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?

Is a placebo-controlled trial anticipated?

6 Answers available

Do you consider downstaging neoadjuvant cemiplimab for borderline resectable CSCC in order to facilitate surgical resection?

3 Answers available

How do you approach patients with a new primary melanoma, not an in-transit metastasis, while on adjuvant immunotherapy/treatment for a previous melanoma lesion?

2 Answers available

How do you approach patients with early stage resected melanoma (Stage IIA) for adjuvant treatment?

1 Answer available

What scenario would prophylactic Tocilizumab be considered to prevent Ipilimumab+Nivolumab (immunotherapy) induced toxicity in malignant melanoma?

1 Answer available

How would you treat an SCC of the helix of the ear with posterior auricular nerve involvement s/p surgical resection?

If there are no pre-op photos, what would your fields look like and dose/fractionation?

1 Answer available

Do you always excise down to the fascia when treating invasive melanomas and does body site location influence the depth of excision?

1 Answer available

What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?

3 Answers available

What oral therapies do you most commonly recommend for skin cancer prevention?

1 Answer available

How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?

If the patient had no nodal sampling, would this influence your decision?

1 Answer available

Is close observation a reasonable option for elderly patients with a small basal cell carcinoma of the face?

1 Answer available

What scenario would flipped dosing versus standard dosing of ipilimumab + nivolumab be beneficial in metastatic melanoma?

CheckMate 511 trial showed reduced toxicity with flipped dosing of ipilimumab/ nivolumab (ipi 1 mg/kg and nivo 3 mg/kg instead of ipi 3 mg/kg and nivo...

1 Answer available

What is your next step in management for a patient with immunotherapy induced pneumonitis that does not improve on high dose steroids for 48 hours?

How do you decide between starting infliximab, MMF, or IVIG? If a patient presents in respiratory failure (nearing or requiring intubation), woul...

1 Answer available

How would you approach a patient with malignant spindle cell neoplasm of the scalp excised with a focally positive deep margin?

What dose and margins would you use? The patient is s/p a liver transplant on immunosuppression.

3 Answers available

How would you treat a melanoma of the penile skin in a medically inoperable patient?

If radiation, what dose/fractionation and technique?

2 Answers available

How do you approach patients with recurrent BRAF negative melanoma and resected oligo-metastasis after completing one year of adjuvant nivolumab?

1 Answer available

In what scenario would you add systemic therapy with adjuvant radiation therapy in resected, locally-advanced, cutaneous squamous cell carcinoma?

Reference: TROG 05.01 Trial

1 Answer available

Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?

1 Answer available

Do you get routine MRI brain for surveillance on patients with history of stage III melanoma?

2 Answers available

In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?

1 Answer available

Would you consider adjuvant radiation in a patient with stage 1 (<1 cm) Merkel cell carcinoma of the lateral upper arm status post resection to negative wide margins?

Sentinel lymph node assessment was negative and there are no other high risk features.

1 Answer available

Do you recommend a deep shave biopsy or punch biopsy for sampling concerning melanocytic lesions?

3 Answers available

Do you hold mTOR inhibitors during radiation?

If so, how long pre- and post-RT?

1 Answer available

What dose-fractionation would you use for cutaneous head and neck squamous cell carcinoma status post resection and skin grafting?

Would you offer adjuvant hypofractionated radiation therapy over a graft in the HN region?

2 Answers available

Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?

2 Answers available

When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies such as TSH/ACTH, or only when a patient has symptoms?

If so, how often do you check these labs?

1 Answer available

Would you offer radiation therapy post lumpectomy for a small melanoma oligometastasis with negative margins?

If so, would you favor 30 Gy/5 fraction accelerated partial breast irradiation?

2 Answers available

Based on the results of SWOG S1801, neoadjuvant vs adjuvant pembrolizumab for resected stage IIIB-IV melanoma, are you starting to recommend neoadjuvant pembro for your patients?

ESMO Congress 2022 Abstract

2 Answers available

Are there any situations in which you would treat a cutaneous in-situ squamous cell carcinoma of the head and neck with radiation?

1 Answer available

What is the significance of PNI in cutaneous BCC?

What level of PNI is considered "large nerve" in this disease?

2 Answers available

How do you treat non-melanomatous skin cancers in poorly vascularized tissue?

This is an elderly patient with a BCC/SCC over the shin who is not eligible for Mohs due to concern for wound-healing issues. Orthovoltage/superficial...

3 Answers available

In a patient with solitary metastasis skin/subcutaneous wrist, resected with graft, from a primary breast angiosarcoma, what would be your preferred fields and dose?

50+ yo F. Mastectomy, chemo, and RT in 2016 for primary breast angiosarcoma, not RT induced. Had longstanding cyst on wrist, biopsied, and positive fo...

2 Answers available

What therapies do you most commonly utilize for patients with SCC in situ on the head and neck?

Do you favor topical treatments or surgical management?

2 Answers available

Among the metastatic/unresectable melanoma patients you would historically treat with anti-PD-1 monotherapy, are you now recommending nivolumab/relatlimab instead?

1 Answer available

Do you consider a solitary IHC+ sentinel inguinal node lymph node to have the same implication for treatment as a single positive node or multiple positive nodes?

Pt with 1.3 cm Merkel cell (buttock) excised with negative margins. Two sentinel inguinal nodes sampled and one is IHC+.

1 Answer available

What is your treatment approach to patients with confluent actinic keratoses on lower extremities?

Does topical 5FU cause eruptive keratoacanthomas or have any other concerning side effects?

2 Answers available

What prescription or over-the-counter therapies do you recommend for patients with side effects from vismodegib?

Have you had success with therapies such as L- carnitine and other remedies?

1 Answer available

What would your radiation volume be for a patient with SCC just medial to the infraorbital foramen with positive PNI who presented with pain s/p regional excision?

Post-operative MRI focused on CN V was negative. There is a focal positive margin.

2 Answers available

How would you approach a cutaneous squamous cell carcinoma with primary tumor completely excised, but multiple foci of LVI at the peripheral specimen margin and no other high-risk features?

Would you consider re-excision and/or adjuvant RT? If RT, what margins on the scar and treatment volume would you use?

2 Answers available

When would you offer post-op radiation for the treatment of sebaceous carcinoma of the eyelid?

2 Answers available

Would you irradiate elective lymph nodes for a T1 Merkel cell carcinoma of the head and neck with a negative sentinel lymph node?

Would a history of immunosuppression impact your decision?

1 Answer available

What dose would you use for re-irradiation of metastatic melanoma to an inguinal node?

If the inguinal node was previously treated with SBRT 30Gy/5fx and immunotherapy >6 months, what treatment would you recommend?

2 Answers available

What protocol do you follow when performing staged excision with paraffin sections for the treatment of cutaneous melanoma?

If you perform MART-1 staining, what protocol do you follow?

1 Answer available

Do you utilize surgical and medical treatments when treating patients with erythroplasia of queyrat, bowenoid papulosis or giant condyloma acuminatum?

1 Answer available

Do you routinely collect debulking specimens for paraffin-embedded or frozen section staining prior to taking a Mohs layer for all skin cancers?

If not, what tumor characteristics prompt you to collect debulking specimens for paraffin or frozen section staining?

3 Answers available

What are your preferred IHC stain(s) for desmoplastic melanoma?

1 Answer available

In your experience, what has been the most effective form of field therapy for your patients with higher burdens of actinic keratoses?

And what factors push you towards the selection of a specific treatment modality?

2 Answers available

What are your top takeaways in Melanoma from ASCO 2022?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

1 Answer available

Would you offer adjuvant radiation therapy for a Merkel cell carcinoma limited to the epidermis with close margins?

1 Answer available

Which patients with cSCC could you omit adjuvant radiation following pathologic complete response following cemiplimab?

1 Answer available

What is the incidence of melanoma arising from vitiliginous patches, and do they develop from different mechanisms than melanomas arising from normal skin?

1 Answer available

Would you offer adjuvant radiation for a sebaceous carcinoma of head and neck after wide local excision?

LVSI positive. No other high-risk features. Would you cover lymphatics?

1 Answer available

How would you manage the axilla in a patient with Merkel cell carcinoma of the left forearm with clinically negative, axillary sentinel node positive disease?

Would you recommend axillary dissection, axillary dissection followed by adjuvant radiation, or axillary radiation alone? Does the number of positive ...

1 Answer available

Do you stop PPI when starting patients on immunotherapy?

1 Answer available

Do you treat the ipsilateral neck and primary site for a resected skin cancer with parotid mets?

If the only indication were the parotid mets (primary site resected with no high risk features) would you treat the parotid and neck (assuming skin ca...

1 Answer available

Would you offer adjuvant radiotherapy to an elderly patient with T4 SCC of the scalp and positive margins 6 months after Mohs surgery?

Would you offer RT if there was bone invasion? If there was poor wound healing causing a 6 months delay, would you still offer RT?

1 Answer available

Would you include interconnecting skin in the radiation volume for a patient with lateral forehead squamous cell carcinoma who will receive radiation to the surgical bed and preauricular lymph nodes?

2 Answers available

Would you consider lymph node basin radiation in a patient with upper extremity Merkel cell carcinoma with one positive SLN but with no other positive lymph nodes found on axillary dissection?

1 Answer available

How would you approach treatment of an elderly patient with recurrent atypical fibroxanthoma (malignant spindle cell neoplasm) after Mohs surgery?

What is the role for surgery vs RT?

1 Answer available

What dose/fractionation would you consider for SBRT of uveal melanomas too large for plaque brachytherapy?

2 Answers available

How would you manage eccrine porocarcinoma of the great toe with positive superficial groin and pelvic lymph nodes s/p toe amputation and pelvic lymph node dissection?

Would you offer systemic therapy and/or radiation therapy to groin/pelvis?

1 Answer available

If a BRAF-mutated melanoma patient developed metastatic disease progression on adjuvant anti-PD-1 monotherapy, do you recommend switching to BRAF/MEK targeted therapy or combination nivolumab/ipilimumab?

2 Answers available

What is the role of radiotherapy in medically inoperable, large and or recurrent aggressive basal cell or squamous cell cancer of the skin in high risk areas?

Should definitive radiotherapy be used as a standard approach? If so, what are the dose and technique considerations in treating these complicated tum...

3 Answers available

Would you ever consider SBRT for de novo cutaneous squamous cell carcinoma?

Is there any data to support it? What dose/fractionation would you consider?

1 Answer available

What radiation regimen do you use to palliate bulky melanoma metastases involving the oral cavity?

In this case, I have a patient with widely metastatic cutaneous melanoma (BRAF wild type, NRAS mutated) who is progressing through pembrolizumab and i...

2 Answers available

When would you add an extra radiation dose to compensate for treatment breaks?

Apart from H&N SCC, are there times where adding an extra dose of radiation due to a tx break is appropriate? Is there a decent equatio...

2 Answers available

How would you treat a high risk Merkel cell carcinoma of the lower leg after R1 re-resection who failed sentinel mapping?

Would you treat the primary site only, include popliteal nodes, or include popliteal and inguinal nodes?

1 Answer available

What is the role of radiation therapy in a patient with diffuse cutaneous melanoma metastases who cannot tolerate systemic therapy?

1 Answer available

What is your preferred radiation therapy technique for treating resected neurotropic squamous cell carcinoma of the facial skin situated near the infraorbital foramen?

3 Answers available

How would you manage a resectable satellite/in-transit melanoma recurrence that developed during adjuvant immunotherapy?

1 Answer available

How would you treat an immunosuppressed patient with high risk cutaneous SCC of the axilla with node positivity on axillary node dissection?

What radiation doses would you use for the scar and axillary nodal regions? Should supraclavicular and/or IMNs be covered?

1 Answer available

What immunosuppressive agents would be available to patients with a history of melanoma?

Would you use immunosuppression in patients several years after curative treatment for melanoma?

1 Answer available

In what clinical circumstances would you consider re-irradiation for skin cancer?

Would you choose re-treatment with electrons, photons, or brachytherapy? What dose and fractionation scheme would you employ?

1 Answer available

How would you manage a nodal recurrence of cutaneous SCC if the patient is unable to receive surgery for 6-8 weeks?

In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...

1 Answer available

How do you recommend differentiating between localized cutaneous melanoma of the perianal skin versus mucosal melanoma of anal canal?

This question arises from a case of a patient with multifocal nodular melanoma with circumferential involvement of the perianal region.

1 Answer available

How do you approach selection of dose and fractionation for definitive treatment of localized skin cancers?

With so many choices listed in NCCN guidelines ranging from 2-7 weeks, what considerations factor into your decision making?

2 Answers available

How do you approach breast conserving therapy in a woman who has formed bothersome keloids after prior surgeries?

Is there any alteration in approach from the medical, surgical, or radiation oncology perspective that can mitigate the risk of forming keloids withou...

3 Answers available

What is your preferred first-line treatment for metastatic melanoma in a patient with a class 2/non-V600 BRAF mutation?

4 Answers available

What is your preferred adjuvant treatment option for a patient with stage III BRAF-mutated melanoma and a history of a solid organ transplantation on immunosuppressants?

0 Answers available

Would you offer adjuvant immunotherapy for a melanoma patient with lymphocytic colitis?

1 Answer available

How would you approach an early inguinal recurrence after surgical resection of Merkel Cell carcinoma in the popliteal region?

2 Answers available

How would you approach radiation treatment of recurrent, BRAF-negative melanoma with left distal leg metastases and two isolated PET-avid inguinal nodes?

The index lesion was located inferior to the left knee and excised appropriately, with an additional in-transit metastasis in the left mid leg. The pa...

1 Answer available

How would you manage a patient with cutaneous SCC of the lower extremity with isolated inguinal nodal involvement?

What is the role and sequence of surgery and/or RT? Which nodal levels would you include in your RT field(s)?

1 Answer available

What is the preferred dose and fractionation regimen for cutaneous squamous cell carcinoma of the thumb?

How would your treatment change for definitive vs post-surgical RT? Does approach differ depending on the anatomic (distal vs proximal and dorsal vs ...

2 Answers available

How do you approach treatment for a patient with uveal melanoma who is not a candidate for plaque brachytherapy

What are the surgical and radiation options? What dose and fractionation scheme is appropriate for fractionated SRS?

2 Answers available

Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

3 Answers available

Would you pursue adjuvant immunotherapy for a resected stage IIIC or IIID, BRAF wild type, melanoma patient with pre-existing ulcerative colitis that is well managed on maintenance infliximab?

1 Answer available

How would you manage recurrent popliteal and inguinal LNs from melanoma?

In a patient with a history of a RLE melanoma s/p WLE and right ILND, how would you treat nodal recurrence? What are the surgical vs non-surgical opt...

1 Answer available

What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?

Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in re...

2 Answers available

How would you treat a patient with an keratoacanthoma of the right nasal ala?

What approaches (surgical vs non-surgical) offer the best cosmesis for keratoacanthoma (low grade squamous cell carcinoma) ?

1 Answer available

What type of surveillance would you recommend following resection of primary mucinous carcinoma of the skin?

1 Answer available

How would you approach treatment of a patient with asymptomatic, oligometastatic basal cell carcinoma?

Is there a role for radiation? Does your approach differ depending on site(s) of disease, and/or if the patient has Basal-Cell Nevus (Gorlin) sy...

1 Answer available

How do you advise patients on the risk for permanent alopecia following RT to the scalp?

In treating skin cancers of the scalp, are there any specific constraints you give to the skin itself to prevent alopecia? How does changi...

2 Answers available

How would you approach the treatment of a patient with a history of cutaneous melanoma and only overt site of disease being a bulky level III axillary lymph node?

Specifically, this patient was unable to tolerate immunotherapy due to severe side effects.

3 Answers available

Would you offer definitive radiation therapy for a Merkel cell carcinoma in which surgical resection would be disfiguring or result in significant dysfunction?

In general, how would you approach such a case with regards to creation of your treatment volumes and dose-fractionation?

1 Answer available

For Merkel cell carcinoma of the lower extremity with early isolated recurrence in the ipsilateral inguinal nodes, would you include pelvic lymph nodes in the post-operative field following inguinal lymph node dissection?

1 Answer available

How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?

1 Answer available

How do you manage MEK inhibitor induced ocular adverse events?

1 Answer available

What is your preferred radiotherapy regimen for palliative treatment of cutaneous T cell lymphoma?

1 Answer available

How would you manage a small recurrent melanoma of the lower eyelid in a patient deemed inoperable?

Would you recommend radiation therapy or immunotherapy? If proceeding with radiation therapy, what dose-fractionation and technique would you utilize?

2 Answers available

Would you recommend post-op RT for an ulcerated Clark's level IV melanoma of the zygomatic/preauricular region following a WLE with diffuse melanoma in-situ at the margins?

What dose-fractionation schedule would you utilize?

1 Answer available

What is the appropriate radiation dose/volume for perianal basal cell carcinoma?

Should concurrent chemotherapy be given? How would you modify the regimen in elderly/frail patients?

1 Answer available

When, if ever, would you consider using encorafenib/binimetinib or vemurafenib/cobimetinib instead of dabrafenib/trametinib for adjuvant treatment of BRAF mutated melanoma?

0 Answers available

Would you treat a locally advanced head and neck cutaneous squamous cell carcinoma with axillary-only mets definitively?

Would you treat with radiation (+/- surgery upfront, if resectable) or systemic therapy?

1 Answer available

What is your approach to adjuvant radiation for anorectal mucosal melanoma s/p wide local excision?

What dose, fractionation and what elective coverage do you recommend?

1 Answer available

What is your approach to elective radiation of the neck with primary cutaneous squamous cell carcinoma?

When do you electively treat the ipsilateral versus ipsi- and contralateral neck?

1 Answer available

Would you start neoadjuvant treatment with immunotherapy or BRAF/MEK inhibitors in a patient with a large regional inoperable BRAF V600E positive melanoma (IIIC)?

1 Answer available

Is there a role for adjuvant therapy, either radiation (+/- chemo), or systemic therapies (immunotherapy, targeted agents or chemotherapy) after resection of anorectal mucosal melanoma?

1 Answer available

How would you approach the treatment of a low grade adnexal carcinoma of the scalp in a patient with prior history of WBRT as a child?

This particular case involves a patient with a frontal scalp low grade eccrine carcinoma status-post excision with positive margin complicated by...

1 Answer available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available

What dose-fractionation and technique do you use when treating lentigo maligna?

3 Answers available

What is your preferred setup/immobilization for patients with cutaneous malignancy of the toe involving the medial aspect of the digit?

1 Answer available

What dose and fractionation would you use for definitive intent radiation therapy for a metastatic melanoma of the maxillary sinus?

1 Answer available

How would you approach treatment of residual melanoma in situ of the perianal skin?

Would you recommend adjuvant radiotherapy for a patient with positive margins for in situ disease with negative margins for invasive disease? If so, w...

1 Answer available

Is postoperative radiotherapy indicated for a primary parotid gland melanoma?

Would there be any indication for postoperative RT if cervical lymph nodes are negative?

1 Answer available

How do you decide between initial radiotherapy vs systemic therapy in patients with metastatic melanoma and brain metastases?

If neurologic symptoms are absent or controlled, does that affect your treatment decision?

2 Answers available

How would you treat a bulky axillary squamous cell carcinoma of unknown primary in an elderly person?

Assuming no other sites of disease on staging scans, surgery is not an option, and the patient is otherwise healthy with reasonable life expectancy. W...

3 Answers available

Would you consider post-operative radiation therapy for resected malignant melanoma with in-transit metastasis?

In this example, the patient had a resected melanoma with negative margins and the specimen was noted to have two nests of tumor cells in the deep der...

1 Answer available

Would you consider starting immunotherapy concurrently with whole brain radiation for newly diagnosed metastatic (BRAF negative) melanoma with multifocal symptomatic brain metastases?

If so, would you consider it with monotherapy only or also with combined checkpoint blockade?

2 Answers available

Would you offer adjuvant RT for a small merkel cell carcinoma of the lateral canthus with a close margin?

Given the location but no other high risk features would you offer RT? If so, what dose and fields?

2 Answers available

Do you ever recommend concurrent chemotherapy for high risk squamous cell skin cancer radiation?

What dose of radiation, what type of chemo, and what indications?

2 Answers available

What are the alternatives to gonioscopy gel to protect the cornea when using internal eye shielding?

In patients with cancers involving the lid requiring superficial x-ray treatment, I use an internal eye shield placed under the lid to protect the cor...

1 Answer available

What dose-fractionation would you utilize for an unresectable localized cutaneous melanoma that has progressed on immunotherapy?

Specifically, for a melanoma of the axilla with proximity to the brachial plexus, how would you approach such a case to minimize chance of radiation-i...

1 Answer available

What dose-fractionation would you recommend for post-operative radiation therapy for an excised cutaneous squamous cell carcinoma of the foot with a skin graft?

Is there an appropriate hypofractionated regimen for such a clinical scenario?

3 Answers available

What is the most appropriate dose-fractionation for an early stage, progressive cutaneous squamous cell carcinoma of the nose in an elderly/frail patient in the setting of the COVID-19 pandemic?

How do counsel patients regarding potential for cartilage necrosis?

5 Answers available

When do you change treatment for an asymptomatic metastatic melanoma with a mixed response after at least 3 months of treatment with a PD-L1 inhibitor?

1 Answer available

Is there any contraindication to concurrent administration of radioactive iodine in a patient on immunotherapy?

A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.

1 Answer available

If small cell carcinoma was found in an axillary lymph node with an unknown primary, would you recommend axillary lymph node dissection prior to chemoradiation?

What would your dosing recommendation be?

2 Answers available

Would you recommend adjuvant radiation for an atypical fibroxanthoma of the scalp that is completed resected with +PNI and +LVI?

What pathologic features are most important when evaluating the possible need for adjuvant therapy?

1 Answer available

Would you offer concurrent chemoradiotherapy and/or adjuvant systemic therapy (chemo or immunotherapy) or for a completely resected stage III Merkel cell after WLE and ALND?

Patient is a 67yo with a pT1 (2.5mm) pN1a merkel cell of the chest, 1 mm deep, widely clear margins, SLN with 1.5mm met, 11 additional axillary ...

2 Answers available

How do you measure the skin dose when you are concerned about dosing to the skin?

Is it possible to get a good measurement with TLDs? TLDs can overestimate the surface dose by 10 - 40%. Do you use a skin diode measurement on the fir...

1 Answer available

For a patient with limited/resectable metastatic melanoma and no evidence of disease after resection, when would you consider doublet immunotherapy rather than nivolumab or pembrolizumab monotherapy?

For instance, in a patient with isolated distant nodal involvement who had the lymph node resected but did not have a lymph node dissection?

1 Answer available

What is your preferred dose-fractionation regimen when treating high-risk SCC of the skin in elderly and/or frail patients?

3 Answers available

How do you manage local recurrence of a resected stage III BRAF WT melanoma occurring during or shortly after completion of adjuvant nivolumab?

Would you offer nodal dissection and/or additional adjuvant immunotherapy in addition to wide local excision?

1 Answer available

How would you manage a high risk SCC of the scalp that has wound healing issues after Mohs surgery?

Would you offer RT? If so, shat dose fractionation do you recommend?

2 Answers available

When should proton beam therapy be considered for uveal melanoma?

Are there exclusion criteria?

3 Answers available

Is there a maximum time delay in offering adjuvant radiation to patients with wound healing issues for sarcoma and skin cancer patients with aggressive histology and positive margins?

Sometimes wound healing can delay adjuvant radiotherapy by several months. For aggressive histology, such as high grade sarcomas or skin cancers with&...

1 Answer available

Would you offer adjuvant radiation to the surgical bed for a Merkel cell carcinoma of the upper extremity with low-risk features as per the NCCN Guidelines?

*Negative margins, <1cm in size, no LVI, negative SLNB, not immunocompromised, no prior surgery (as well as a negative PET/CT scan).

2 Answers available

What radiation dose, fractionation and volume would you use in an elderly patient with localized extensive anorectal malignant melanoma status post laparoscopic APR?

Would your recommendation change with the following aggressive features: 8 cm, pericolic extension, positive radial margin, perineural invasion presen...

1 Answer available

How do you decide whether or not to give immunotherapy in patients with a history of an isolated, severe autoimmune event?

For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...

1 Answer available

What dose-fractionation would you use for a recurrent basal cell carcinoma of the right ear concha close to the tympanic membrane status-post multiple Mohs surgeries with close/positive margins?

Further resection is not recommended, as the surgeon is worried about damaging hearing with additional surgery.

2 Answers available

How do you account for tumor growth from pre-operative to intra-operative ultrasound for uveal melanoma?

Do you prescribe to 5mm/apex or use a margin? Do you add time for tumor growth or allow less than the prescription dose to the apex?

2 Answers available

What therapy would you offer a young BRAF wild type patient with metastatic melanoma, who progressed on single agent pembrolizumab?

1 Answer available

How do your adjuvant treatment recommendations change, if at all, for clinically node positive Stage III desmoplastic melanoma?

1 Answer available

Are there guidlines for elective coverage of nodal basins in head and neck for skin cancer removed in the area?

4 Answers available

What dose-fractionation do you use for recurrent SCC (face) that was previously multiply resected and radiated, but has a persistently positive margin after re-resection?

Especially in the setting of prior “standard” adjuvant dose and refusal of the patient to undergo more extensive surgery. Do you recommend...

1 Answer available

For clinically node negative large squamous cell carcinomas of the scalp vertex, would you electively treat the nodes?

If so, which levels? Bilateral? What about parotids or submandibular gland?

1 Answer available

How do you prevent non-healing ulcer when treating patients with cutaneous SCC of the distal lower extremity who have peripheral vascular disease?

These patients are often not surgical candidates, but radiation complications may also be underappreciated. Do you refer to vascular surgery pri...

2 Answers available

When is postoperative radiation indicated after enucleation of an ocular melanoma?

Is extrascleral extension or optic nerve invasion an indication? I can find little in the literature or textbooks discussing this issue, likely ...

1 Answer available

How would you treat a patient with BRAF mutated Metastatic Melanoma who has progressed on targeted therapy (Encorafenib + Binimetinib) and Immuotherapy (Nivolumab/Ipilimumab), but yet maintain an excellent performance status?

2 Answers available

Can you use immunotherapy in patients with liver transplants?

With increasing utility of immunotherapy across cancer types, patients with history of solid organ transplants may face need for cancer IO. How do you...

1 Answer available

What are your dose constraints for treating axillary nodal basin in melanoma with 30Gy/5fx?

What are your dose constraints for treating axillary nodal basin in melanoma with the Ballo protocol 30Gy/5fx?

1 Answer available

When do you consider employing the 4-week dosing schedule for nivolumab?

The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...

5 Answers available

Is there a role for treating actinic keratosis with superficial radiation therapy to widespread areas on scalp?

If so, what is your suggested dose/fractionation?

1 Answer available

Is there a role for radiation in the treatment of bulky axillary adenopathy in patients with newly diagnosed oligometastatic melanoma?

Should these patients have surgery if resectable? Should RT (SBRT) be directed at metastases during/concurrently with immunotherapy down the road?&nbs...

1 Answer available

Would you recommend surgery +/- adjuvant XRT or definitive XRT in elderly patients with recurrent squamous cell carcinoma of the ear with direct invasion through the cartilage of the helix?

1 Answer available

What is the role of adjuvant radiation therapy for isolated melanoma lymph node metastases, status post resection and found to have extranodal extension?

1 Answer available

What would be your recommended adjuvant treatment approach for a completely excised lymphoepithelial carcinoma of the right nose recurrent in a left level IB lymph node, status-post excisional biopsy?

Would you recommend additional surgery for the violated neck? Or, would you proceed with adjuvant radiation therapy? If so, would you treat ipsilatera...

1 Answer available

What are your recommendation for vaccines in patients while on immunotherapy?

Do you recommend or withhold influenza and pneumonia vaccines while on treatment with checkpoint inhibitors?

1 Answer available

Would you give adjuvant nivolumab for IIIA melanoma?

Patients with T3aN1a( stage IIIA per AJCC7) were excluded from nivolumab adjuvant trial. Would you consider nivolumab in these patients?

1 Answer available

How would you approach adjuvant radiation therapy for a Merkel cell carcinoma of the cheek in an immunocompromised patient?

For example, in a patient status-post WLE with a close (2.5 mm) deep margin and negative neck node sampling, would clinical (but not pathologic) ...

1 Answer available

How would you approach a patient who progressed on immunotherapy for merkel cell carcinoma?

Checkpoint inhibitors have demonstrated durable responses in clinical trials, which was never seen with cytotoxic chemotherapy in the past. What are t...

1 Answer available

What is your approach to metastatic choroidal melanoma with systemic metastases outside of a clinical trial?

NCCN guidelines recommend both single agent Pembro and/or Ipi/Nivo as first line options. How would you choose between the two? In case of the latter,...

1 Answer available

What is the role of Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma?

The FDA recently approved Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma. When would they be ...

1 Answer available

How would you treat a patient with aggressive metastatic cutaneous squamous cell carcinoma, which is not amenable to surgery or radiation?

2 Answers available

When would you consider neoadjuvant immunotherapy for advanced melanoma?

For example, would you consider this in a patient that would otherwise be eligible for adjuvant treatment (stage III or stage IV with oligometastatic ...

1 Answer available

What dose and fractionation would you recommend for treating the primary site of a patient with metastatic anal melanoma?

1 Answer available

What do you consider to be the regional nodal bed for a Merkel cell carcinoma of the thigh with a positive sentinel node in the inguinal chain?

Would you also radiate the ipsalateral external and/or common iliac nodes?

2 Answers available

In what situations would you treat elective regional lymph nodes for a squamous cell carcinoma of the skin on the extremity/trunk that was clinically node negative?

For example, for a squamous cell carcinoma of the forearm treated with Mohs surgery with negative margins, are there features that would lead you to e...

1 Answer available

When is adjuvant radiotherapy recommended for a high risk squamous cell carcinoma of the skin (non-H&N) if the tumor is resected with widely negative margins and there is no perineural invasion?

Per NCCN, only +/close margins and +PNI are given as indications for adjuvant RT. However, are the presence of other risks factors considered to guide...

1 Answer available

Would you hold immunotherapy if a patient with metastatic melanoma has stable disease for 6 months?

If so, after what duration?

1 Answer available

Would you consider stopping nivo/ipi combination after a CR in a patient with metastatic melanoma?

Can you extrapolate the data on Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma to patients on a...

1 Answer available

How long after achieving a CR would you consider stopping pembrolizumab in metastatic melanoma?

1 Answer available

Is there a role for radiation therapy if squamous cell carcinoma (SCC) is incidentally found in an excised epidermoid cyst?

If the cyst was encapsulated and completely removed and SCC was found incidentally on final pathology, what are some factors that would influence your...

1 Answer available

What is the your choice of treatment after progression or AE following pembrolizumab in metastatic melanoma?

Patient does not have BRAF mutation.

1 Answer available

Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?

In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive?

1 Answer available

What are the indications for adjuvant radiotherapy for basal cell carcinoma of the skin of the head and neck?

NCCN lists only substantial perineural invasion. What about other high-risk adverse features such as histologic subtype, multiple recurrences, d...

1 Answer available

What dose fractionation would you recommend for large (>5 cm) perianal Bowen's disease (squamous cell CIS)?

1 Answer available

What is your approach to the initial treatment of metastatic melanoma patients with NRAS mutations?

How do you treat these patients if they progress after immune checkpoint inhibitors?

1 Answer available

What postop volume would you treat for for cutaneous squamous cell carcinoma of the upper neck with perineural invasion of multiple nerves?

Should nodes always be covered for perineural invasion when that is the only risk factor?

1 Answer available

What dose-fractionation would you use to treat a single large melanoma lung metastasis?

How does your fractionation choice change if the lesion is abutting the pleura?

1 Answer available

What systemic therapy, if any, would you recommend for a patient with oligometastatic melanoma who is rendered NED after resection?

Would your recommendation change at all depending on time to relapse or original stage of melanoma?

1 Answer available

What would you recommend as adjuvant treatment for a patient with Stage III melanoma?

If staged so due to satellite lesion and negative nodes? How do you decide between adjuvant PD-1 inhibitor or BRAF/MEK inhibition in BRAF-mutated pati...

1 Answer available

What treatment would you offer to a patient after resection of a solitary metastatic melanoma from the brain without evidence of other sites of disease?

Assuming SRS to the resection cavity is advised, would you recommend early immunotherapy to improve outcomes/enhance a possible abscopal eff...

1 Answer available

Is there a role for PD-1 inhibitors for metastatic or locally recurrent cutaneous squamous cell carcinomas after failure of first line therapy, EGFR inhibitors?

Is it commonly used if no clinical trials are available?

1 Answer available

Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?

These patients have been largely excluded from these trials. What if the infection is well controlled?

3 Answers available

What risk factors prompt you to treat an early-stage nasal squamous cell carcinoma of the skin with post-operative radiation to the primary and/or elective nodal radiation?

When elective nodal radiation is recommended, which nodes would you treat (i.e. facial, pre-auricular, peri-parotid, levels I-III, etc.)?

1 Answer available

Is it necessary to hold immunotherapy during a 4-6wk steroid taper after resolution of immunotherapy related toxicity?

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

1 Answer available

How do you approach treatment for metastatic cutaneous squamous cell carcinoma after standard chemotherapy failure?

Is the use of immunotherapy being considered, and if so, is the data extrapolated from treatment of mNSCLC and head and neck SCC?

1 Answer available

Would you offer adjuvant radiation for a <1 cm preauricular sebaceous carcinoma after wide local excision?

Patient underwent a shave biopsy of a 6x5x2mm preauricular lesion that showed moderatley differentiated sebaceous carcinoma with deep and lateral marg...

1 Answer available

Would you recommend adjuvant radiation therapy to the locoregional lymph node basins for Merkel cell carcinoma (MCC) with a solitary macroscopically positive lymph node (LN) without ECE after lymph node dissection?

Per the NCCN guidelines, in this specific scenario, adjuvant radiation therapy to the locoregional lymph nodes after lymph node dissection is not indi...

2 Answers available

How do you manage the elective lymphatics in high risk squamous cell carcinoma of the skin?

In a clinical N0 patient with high risk (large, deeply invasive, poorly differentiated, +PNI, etc) cutaneous SCC of the head and neck, who do you...

2 Answers available

How do you decide whether or not to cover elective lymphatics when treating cutaneous squamous cell carcinoma of the head and neck with definitive RT?

Unlike in post-operative cases, you lack detailed pathologic information in this scenario. Do you base your decision on location, size, and/or patholo...

2 Answers available

How would you manage treatment of keloid that is so large it requests a graft?

What dose/fractionation would yield the lowest risk of graft failure? Does your treatment management change based of location, ex the ear vs back?

1 Answer available

Do you recommend elective lymph node irradiation for a basal cell carcinoma of the skin that is deeply invading muscle?

For example, would you recommend treatment of the cervical and posterior occipital lymphatics for a 4 cm lesion deeply invading the posterior ridge of...

1 Answer available

Do you consider alternate therapy with a different anti-PD1 agent after a patient responds to an anti-CTLA4 +/- anti-PD1 agent but develops serious side effects?

Is there data for switching from nivolumab/ipilimumab to pembrolizumab if a patient develops significant pneumonitis but also had a significant radiog...

1 Answer available

What is your preferred approach for the management of choroidal oligometastases?

How do you decide between plaque brachytherapy and external beam approaches? What dose do you use for plaque brachytherapy? For external beam, what do...

1 Answer available

How would you utilize adjuvant radiation therapy in a patient with a cutaneous spindle cell neoplasm of the scalp metastatic to the parotid gland?

What dose-fractionation schedule and treatment volumes would you utilize for adjuvant radiation therapy status-post total parotidectomy with negative ...

1 Answer available

When would you recommend adjuvant radiation therapy for a patient with a completely resected (negative margins) dermatofibrosarcoma protuberans?

1 Answer available

Does anaphylactoid reaction to one immunotherapy agent exclude the possibility of using other immunotherapy agents?

1 Answer available

Do you resume immunotherapy (such as nivolumab) for metastatic melanoma after therapy-induced grade 4 hyperglycemia that has resolved?

Can immune check point inhibitor be restarted if grade 4 hyperglycemia (with acidosis and insulin drip requirement) has resolved?

1 Answer available

How do you manage the neck in patients with cutaneous SCC who are at high risk of nodal disease but had a negative neck dissection?

Is there a minimum amount of nodes you would like to be removed before you omit radiation to the neck? Do you consider other factors when deciding whe...

1 Answer available

Is there an effective treatment for multiple appearances of cutaneous Kaposi's lesions besides radiation?

In a patient who already received 13 courses of radiation (with complete response), is there any other effective treatment?

1 Answer available

Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?

Or would you try to wait and get the steroids off first?

1 Answer available

Should lymph nodes be treated with postop RT of undifferentiated pleomorphic sarcoma of the head and neck?

Specifically, the cheek? If so, which nodes should be treated and to what dose?

1 Answer available

How do you approach the management of surgically resected conjunctival melanoma that has recurred locally?

What, if any, is the role of immunotherapy in this situation ?

1 Answer available

In which patients do you offer adjuvant radiation for porocarcinoma?

If a patient has undergone wide local excision with residual disease, but negative margins, is it safe to observe? If adjuvant treatment is indicated,...

1 Answer available

How do you choose between single agent versus combination checkpoint inhibitors for BRAF Wildtype metastatic melanoma?

1 Answer available

How do you manage anticoagulation for patients with DVT/PE who have brain metastases?

Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage. Is t...

3 Answers available

How do you treat multi-focal/diffuse non-melanomatous skin cancers of the face and scalp for which you would also want to cover high-risk elective nodes?

Would you treat large/total scalp fields to definitive skin cancer doses? If the patient has a more limited KPS, would you treat sequentially in order...

2 Answers available

Would you ever consider stopping immunotherapy in a patient with metastatic melanoma after achieving a good response?

Would your recommendations change if it was a partial vs complete radiographic response?

1 Answer available

What is your approach to adjuvant treatment to the tumor bed and/or regional lymph nodes for an early stage Merkel cell carcinoma status-post WLE and sentinel lymph node biopsy?

If there is an operationally failed sentinel lymph node biopsy, do you always include RT to regional nodes?

3 Answers available

Do you have a tolerance dose for a skin graft when treating a high-risk skin cancer?

How long would you typically wait between date of surgery and initiation of radiation therapy? What factors influence this decision?

1 Answer available

How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?

What immunosuppressive agents are used and in what order? Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...

1 Answer available

For newly diagnosed BRAF mutated melanoma with brain metastases, do you prefer to start with targeted therapy or with immunotherapy?

1 Answer available

Do you offer radiation in the setting of a resected desmoplastic melanoma with negative margins given that several retrospective studies show a local control benefit?

If so, how large of a margin would you place on the primary lesion and would you incorporate any adjacent lymph node levels?

3 Answers available

Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population? What about in patients with mild liv...

1 Answer available

How do you manage patients with BRAF V600E-mutated metastatic melanoma who have a mixed radiographic response after several months of therapy with dabrafenib/trametinib?

Does the site of progression or response matter? What if there is progression in the lungs but response in lymphadenopathy, for example?

1 Answer available

How do you manage hematologic toxicities in solid tumor patients treated with immune checkpoint inhibitors?

If these are presumed to be immune-mediated (e.g. immune neutropenia or immune thrombocytopenia), do you treat with steroids?

1 Answer available

Do you recommend using altered fractionation for a patient with squamous cell carcinoma of the skin in the head and neck region who cannot receive concurrent chemotherapy?

For example, if you had an octogenarian with a previously resected squamous cell carcinoma of the skin who presented with metastases to the parotid an...

1 Answer available

How do you manage an acute herpes zoster infection (shingles) in a radiation therapy treatment field where the skin is getting a significant dose of RT?

Do you give a treatment break? Is so, how long should RT be held? Are there skin management techniques to use?

1 Answer available

For a localized hidradenocarcinoma of the extremity managed with resection, what adjuvant dose to the surgical bed would you recommend?

Would this recommendation change based on proximity to a joint?

1 Answer available

When does perineural invasion for a squamous cell carcinoma of the skin of the head and neck merit adjuvant radiotherapy?

Following Mohs surgery and in the absence of other high risk features, do you offer RT for any PNI? A single nerve < 0.1 mm? A single ne...

3 Answers available

How would you treat an unresectable SCC of the skin local recurrence in the base of skull with clinical and radiographic CN involvement?

Would you be comfortable with 55Gy in 20 fractions around the optic nerves and brainstem, or would you treat with a more protracted fractionation? Do ...

3 Answers available

What is the best management for recurrent basal cell carcinoma after prior radiation and vismodegib?

Would re-irradiation be an appropriate option? What dose/field would you incorporate? If treating with standard fractionation, would you take the enti...

1 Answer available

How do you manage an open wound that is not healing after radiation treatment for an ulcerated SCC of the scalp?

If the patient is a poor surgical candidate and is a symptomatic, can he or she live with this?

1 Answer available

How do you address the risks of radiation-induced carcinogenesis when counseling younger adult patients (40-60 years old) on definitive radiation therapy for non-melanomatous skin cancer of the head/neck?

Is there an age where the patient would be considered "too young" to receive definitive radiation therapy as opposed to surgery?

1 Answer available

How should RT be combined with immunotherapy to generate an abscopal response?

Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...

1 Answer available

What should be the first line treatment for metastatic uveal melanoma?

1 Answer available

What is your approach to patients with stage III melanoma now that the FDA has approved adjuvant ipilimumab for high risk stage III melanoma patients?

1 Answer available

Do you treat fully resected squamous cell carcinoma of the ear with cartilage invasion with adjuvant radiation?

If so, what is your treatment volume?

1 Answer available

How do you manage dabrafenib fever?

Decrease the dose? Treatment break? Steroids?

1 Answer available

When treating a high risk cutaneous squamous cell carcinoma post-operatively to the tumor bed, do you include the entire pre-op tumor in your PTV or do you include only the scar with margin?

For example, if a 5 x 5 cm squamaous cell carcinoma with deep invasion has been resected via Mohs with negative margins, will your PTV include the ent...

1 Answer available

What dose and fractionation do you use when you want an abbreviated course for incompletely resected squamous cell carcinoma of the pre-auricular area?

For example, in a demented, poor performance status, elderly patient?

1 Answer available

What is the value of resection in high risk (but small or early stage) skin cancers at the medial canthus?

Is modern surgical/reconstruction treatment superior to radiation therapy? If contact brachytherapy or superficial (orthovoltage) therapy isnt possib...

1 Answer available

Do you treat the surrounding erythema for cutaneous squamous or basal cell carcinoma?

Is the surrounding erythema as part of the GTV so that the margin is placed around the erythema rather than around the gross lesion only?

1 Answer available

What dose do you typically use when retreating locally aggressive and recurrent SCCs of the scalp (with no regional or distant mets)?

Assume all other options have been exhausted or are not feasible (e.g. systemic treatments, medically inoperable, etc.). Is there a BED or EQD2 that y...

1 Answer available

What is the best radiation technique for treating Kaposi sarcoma involving the irregular surfaces of the toes and soles of the feet?

1 Answer available

When should patients with metastatic melanoma be referred for treatment at an academic center?

With novel therapies quickly evolving, it's becoming more difficult to discern the proper sequence of therapies and the point at which a clinical tria...

1 Answer available

For cutaneous SCC of the cheek with microscopic PNI, which nodal levels, if any, do you prophylactically treat?

Do you prophylactically treat the entire parotid gland as well?

1 Answer available

How do you best palliate metastatic skin and subcutaneous melanoma lesions?

Do you hypofractionate or add any concurrent systemic therapy? What specific dose-fractionation regimens do you recommend?

1 Answer available

Is there any data to support radiation and targeted agents (Braf inhibitor or ipilimumab) combined for stage III melanoma?

Even though data from TROG 02.01 showed 52% decrease in LR, I've heard some argue that toxicity is increased and that "it damages the blood vessels an...

1 Answer available

Papers discussed in this category

Oral oncology, 2018-03

Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis.

J. Clin. Oncol., 2018 Mar 14

Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

International journal of radiation oncology, biology, physics, 2004-11-01

Permanent alopecia after cranial irradiation: dose-response relationship.

JAMA Dermatol,

Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.

Blood, 2015-07-23

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.

Cancer, 1995 May 1

Reirradiation of recurrent skin cancer of the face. A successful salvage modality.

Eur. J. Cancer, 2016-02-01

JAMA dermatology, 2016-09-01

Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site.

Ann Surg Oncol, 2003 May

Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma.

American journal of surgery, 2001-12

The clinical behavior of desmoplastic melanoma.

World J Surg, 1992 Mar-Apr

Desmoplastic melanoma: patterns of recurrence.

Cancer, 2005-10-01

Wide excision without radiation for desmoplastic melanoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-01

Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines.

Radiation oncology (London, England), 2015-09-21

Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp.

Immunotherapy, 2016-10

Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.

Med Dosim, 2013 Summer

A case study of radiotherapy planning for Intensity Modulation Radiation Therapy for the whole scalp with matching electron treatment.

Radiother Oncol, 1989-02-01

Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years.

J. Clin. Oncol., 2018-06-10

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

N Engl J Med, 2015 May 31

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Cancer, 2011-10-15

Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience.

International journal of radiation oncology, biology, physics, 2016-06-01

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

The New England journal of medicine, 2017-11-09

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Radiother Oncol, 2002-07-01

External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08).

N. Engl. J. Med., 2017-11-09

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-10

Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis.

Head Neck, 2011-12-01

Cutaneous squamous cell carcinoma of the head and neck metastasizing to the parotid gland--a review of current recommendations.

Br. J. Dermatol.,

Radiotherapy for lentigo maligna: a literature review and recommendations for treatment.

International journal of radiation oncology, biology, physics, 2017-03-15

SBRT in five fractions.

Int. J. Radiat. Oncol. Biol. Phys.,

An Ultracentral Lung Tumor.

Lancet (London, England), 2017-10-21

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

The Lancet. Oncology, 2016-11

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

The New England journal of medicine, 2017-10-05

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

J. Clin. Oncol.,

High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07.

International journal of radiation oncology, biology, physics, 2009-04-01

Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma.

Lancet Oncol, 2018 May

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

The Lancet. Oncology, 2016-10

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

N Engl J Med, 2018 Apr 15

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Lancet Oncol, 2022 Oct 18

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

The New England journal of medicine, 2012-03-08

Immunologic correlates of the abscopal effect in a patient with melanoma.

Practical radiation oncology, 2017

Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT.

PLoS One, 2016

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.

Int. J. Radiat. Oncol. Biol. Phys.,

A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma.

Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

Lancet Oncol., 2017 Mar 04

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Lancet Oncol., 2012 May 09

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

J Surg Oncol, 2018 Dec 18

Indications for the surgical resection of stage IV disease.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-01-15

Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Therapeutic advances in medical oncology, 2018

Radiotherapy and checkpoint inhibitors: a winning new combination?

International journal of radiation oncology, biology, physics, 2002-03-15

Adjuvant irradiation for axillary metastases from malignant melanoma.

Lancet Oncol., 2014-11-01

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Ann. Oncol., 2011 Jul 12

Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.

Journal for immunotherapy of cancer, 2019-06-06

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

J. Clin. Oncol., 2019 Feb 27

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Ophthalmology, 2002-10

Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.

Archives of ophthalmology (Chicago, Ill. : 1960), 2002-12

Evidence-based estimates of outcome in patients irradiated for intraocular melanoma.

Am. J. Ophthalmol.,

The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24.

International journal of radiation oncology, biology, physics, 2001-03-15

Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality.

Int. J. Radiat. Oncol. Biol. Phys., 2017 Feb 17

Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma.

Br J Ophthalmol, 2013 Jan 19

A comparison between ¹²⁵Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma.

JAMA Ophthalmol,

Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection.

International journal of radiation oncology, biology, physics, 2013-05-01

Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis.

International journal of radiation oncology, biology, physics, 2017-01-01

Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.

International journal of radiation oncology, biology, physics, 2015-06-01

Long-term Results of the UCSF-LBNL Randomized Trial: Charged Particle With Helium Ion Versus Iodine-125 Plaque Therapy for Choroidal and Ciliary Body Melanoma.

Int. J. Radiat. Oncol. Biol. Phys.,

Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.

Investigative ophthalmology & visual science, 2006-11

Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture.

PloS one, 2015

Cost-effectiveness of proton beam therapy for intraocular melanoma.

Br J Ophthalmol, 2013 May 03

Local treatment failure after globe-conserving therapy for choroidal melanoma.

Int J Radiat Oncol Biol Phys, 2016 Jan 28

Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey.

Saudi J Ophthalmol,

Proton beam radiotherapy of uveal melanoma.

Journal of contemporary brachytherapy, 2017-04

Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions.

Melanoma research, 2015-04

The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.

Nature, 2018-01-18

High response rate to PD-1 blockade in desmoplastic melanomas.

Cureus, 2019 Jun 18

Desmoplastic Melanoma: Clinical Characteristics and Survival in the US Population.

PloS one, 2015

Clinicopathologic predictors of survival in patients with desmoplastic melanoma.

Semin. Cancer Biol., 2019 Jul 19

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

J Natl Compr Canc Netw,

Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.

Int. J. Radiat. Oncol. Biol. Phys.,

Radiation effect in mouse skin: dose fractionation and wound healing.

J. Clin. Oncol., 2019 Dec 27

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

The British journal of dermatology, 2019-02

Local recurrence and quality of life after adjuvant radiation therapy in high-risk squamous cell carcinoma.

JAAD Case Rep, 2019 Jun 26

Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.

Pract Radiat Oncol, 2019 Dec 09

Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline.

Radiother Oncol, 2010 Mar 23

Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases.

Lancet (London, England), 2004-05-22

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

The Lancet. Oncology, 2016-07

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

International journal of radiation oncology, biology, physics, 2018-03-15

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

The New England journal of medicine, 2018-08-23

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-01

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

J. Clin. Oncol., 2019 Sep 25

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.

Clin Oncol (R Coll Radiol),

Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases.

Lancet Oncol., 2018 Mar 27

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Cochrane Database Syst Rev, 2012 Apr 18

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Cancer, 2016 Jun 10

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.

International journal of radiation oncology, biology, physics, 2017-11-15

Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).

International journal of radiation oncology, biology, physics, 1997-03-01

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

Neurosurgery, 2020 Apr 21

Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases.

J. Am. Acad. Dermatol.,

Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients.

J. Am. Acad. Dermatol., 2011 Oct 24

Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma.

J Am Acad Dermatol, 2019 Sep 25

Restaging [F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance.

JAMA ophthalmology, 2016-08-01

Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.

N Engl J Med, 2022 Sep 12

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

Front Oncol, 2023 Jan 04

Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma.

Br J Dermatol, 2015 Aug 08

Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas.

Lancet Oncol, 2015 Jul 20

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.

N Engl J Med, 2019 Sep 28

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Lancet Oncol, 2019 Dec

Sebaceous carcinoma: evidence-based clinical practice guidelines.

Melanoma research, 2017-06

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

JAMA Dermatol,

Prevalence and Gross Morphologic Features of Perianal Melanocytic Nevi.

Pathology, 2018 Nov 26

Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.

Semin Cancer Biol, 2019 Oct 23

The mutational landscape of mucosal melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-01

Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.

BJS open, 2021 Nov 09

Surgical treatment of anorectal melanoma: a systematic review and meta-analysis.

Journal of medical case reports, 2010-05-22

Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report.

Ann Med Surg (Lond), 2017 Jun 20

Porocarcinoma; presentation and management, a meta-analysis of 453 cases.

Case Rep Oncol, 2021 May 10

Eccrine Porocarcinoma: A Challenging Diagnostic and Therapeutic Tumoral Entity.

J Clin Oncol,

Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials.

Int J Radiat Oncol Biol Phys,

Dosimetric evaluation of lead and tungsten eye shields in electron beam treatment.

Head Neck, 2021 Jun 07

Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review.

Journal of the American College of Surgeons, 2011-04

Shave biopsy is a safe and accurate method for the initial evaluation of melanoma.

Am J Surg,

Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma.

Nature medicine, 2023 Aug 17

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Feb 13

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.

Ann Pharmacother, 2021 Jul 20

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.

Ann Transl Med,

The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Can Fam Physician,

Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.

Dermatol Clin,

Skin Cancer Risk (Nonmelanoma Skin Cancers/Melanoma) in Vitiligo Patients.

J Am Acad Dermatol, 2014 Sep 19

Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.

Br J Dermatol,

Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.

East Afr Med J,

PRIMARY MALIGNANT AMELANOTIC MELANOMA ARISING FROM A VITILIGO PATCH OF AN AFRICAN TANZANIAN: CASE REPORT.

Int J Dermatol,

Molecular analysis of vitiligo lesions reveals sporadic melanocyte survival.

J Pathol,

Melanocytes are not absent in lesional skin of long duration vitiligo.

Sci Rep, 2021 Oct 12

Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan.

Acta Derm Venereol,

Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo.

Br J Dermatol, 2019 Sep 18

The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.

Br J Dermatol, 2019 Oct 16

Vitiligo and skin cancer: is it a question of ethnicity?

J Clin Oncol, 2022 Sep 27

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

J Clin Oncol, 2022 Jan 14

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.

Eur J Cancer, 2021 Nov 17

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

J Immunother Cancer, 2020 Dec

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma.

N Engl J Med,

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

The American Journal of dermatopathology, 2013-07

SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics.

The American journal of surgical pathology, 2018-03

Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.

The American journal of surgical pathology, 2018-11

PRAME Expression in Melanocytic Tumors.

Appl Immunohistochem Mol Morphol,

SOX10 expression in malignant melanoma, carcinoma, and normal tissues.

Pathology, 2016 Aug 28

SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens.

Am J Dermatopathol,

Sox10-Positive Cells Within Scars: A Potential Diagnostic Pitfall.

Am J Dermatopathol,

SOX-10 and S100 Negative Desmoplastic Melanoma: Apropos a Diagnostically Challenging Case.

J Am Acad Dermatol, 2022 Jun 23

Value of Permanent Pathology for Debulk and Mohs Specimens during Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma: A Retrospective Cohort Study.

Dermatol Surg,

Utility of Debulk Specimens During Mohs Micrographic Surgery for Cutaneous Squamous Cell Carcinoma.

Lancet Oncol, 2008 Jul 09

Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.

Int J Radiat Oncol Biol Phys, 2020 Apr 11

Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN).

Journal of the American Academy of Dermatology, 2014-01

Cutaneous squamous cell carcinomas of the lower extremity: a distinct subset of squamous cell carcinomas.

Dermatol Ther (Heidelb), 2015 Aug 25

5-Fluorouracil "Chemowraps" in the Treatment of Multiple Actinic Keratoses: A Norwich Experience.

JAAD Case Rep, 2021 Aug 18

Eruptive keratoacanthomas secondary to topical 5-fluorouracil application.

Melanoma research, 2017-10

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Cancer, 2011-04-15

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 Sep 09

Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment.

European journal of cancer (Oxford, England : 1990), 2017-04

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

American journal of clinical oncology, 2005-12

Head and neck mucosal melanoma.

Head & neck, 2016-01

Update on primary head and neck mucosal melanoma.

The Laryngoscope, 1994-02

Mucosal melanoma of the head and neck: the impact of local control on survival.

Oral and maxillofacial surgery, 2023 Apr 05

Head and neck mucosal melanoma: radiological considerations and UK imaging guidelines.

J Am Acad Dermatol, 2020 May 07

Field cancerization: Definition, epidemiology, risk factors, and outcomes.

J Dermatolog Treat, 2022 May 23

Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-05-01

Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Asia-Pacific journal of clinical oncology, 2020 Aug 05

The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.

Annals of surgical oncology, 2020 May 13

Patterns of Metastasis in Merkel Cell Carcinoma.

Radiother Oncol, 2019 Feb 28

Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis.

J Clin Oncol, 2020 Nov 20

Systemic Therapy for Melanoma: ASCO Guideline.

Lancet Oncol, 2015 Mar 31

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Lancet, 2022 Sep 10

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.

Arch Dermatol, 2010 Jul 19

Variation in the depth of excision of melanoma: A survey of US physicians.

Annals of surgery, 2006-12

The role of abdominoperineal resection as surgical therapy for anorectal melanoma.

Annals of surgical oncology, 2013-07

Locoregional lymphadenectomy in the surgical management of anorectal melanoma.

Annals of surgical oncology, 2010-01

Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?

Diseases of the colon and rectum, 1999-09

Changing epidemiology of anorectal melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-10

Somatic activation of KIT in distinct subtypes of melanoma.

Dermatol Pract Concept, 2019 Jan 31

Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters.

Clin Cancer Res, 2013 Jul 05

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Oct 30

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.

The Lancet. Oncology, 2019 May 31

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Nature, 2022 Oct 26

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Brachytherapy, 2017

Skin surface brachytherapy: A survey of contemporary practice patterns.

Brachytherapy, 2020 Jul - Aug

The American Brachytherapy society consensus statement for skin brachytherapy.

Brachytherapy, 2015 Aug 28

Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report.

International journal of radiation oncology, biology, physics, 2022 Dec 28

A Multicenter Prospective Trial of Electronic Skin Surface Brachytherapy for Keratinocyte Carcinoma: Early Cosmesis, Quality of Life, and Adverse Events.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-02-15

Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Dec 01

Dissecting the Need for Adjuvant Therapy in Patients With Early-Stage Melanoma With Micrometastases.

Cancer, 2023 Mar 04

Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.

Journal for immunotherapy of cancer, 2022 Aug

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.

N Engl J Med, 2017 Jun 8

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Journal of the American Academy of Dermatology, 2019 Dec 10

Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.

The oncologist, 2021 May 31

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.

Melanoma/Skin Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics